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Edited by Varda RotterAbstract The known members of inhibitor of growth (ING)
gene family are considered as candidate tumor suppressor genes.
ING4, a novel member of ING family, is recently reported to
interact with tumor suppressor p53, p300 (a major component of
histone acetyl transferase complexes), and p65(RelA) subunit
of NF-jB. In this study, we investigated the cellular behaviors of
HepG2 cells with exogenous ING4. Interestingly, the overex-
pression of ING4 negatively regulated the cell growth with
signiﬁcant G2/M arrest of cell cycle, and moreover, enhanced the
cell apoptosis triggered by serum starvation in HepG2 cells.
Furthermore, the exogenous ING4 could upregulate endogenous
p21 and Bax in HepG2 cells, not in p53-deﬁcient Saos-2 cells,
suggesting that G2/M arrest induced by ING4 could be mediated
by the increased p21 expression in a p53-dependent manner,
although there is no signiﬁcant increase of p53 expression in
HepG2 cells. Moreover, HepG2 cells with exogenous ING4
could signiﬁcantly increase cell death, as exposed to some DNA-
damage agents, such as etoposide and doxorubicin, implying that
ING4 could enhance chemosensitivity to certain DNA-damage
agents in HepG2 cells.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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ING1, as the ﬁrst member of the inhibitor of growth (ING)
gene family, was identiﬁed by subtractive hybridization and
the subsequent selection of transforming ‘genetic suppressor
elements’ [1]. The described ING1 was renamed as ING1b,
since two additionally alternative splicing variants of ING1
gene were found [2,3]. Interestingly, the previous studies indi-
cated that the expression of ING1 could be signiﬁcantly
involved in the regulation of apoptosis and cell cycle in a p53-
dependent manner in several cancers and cell lines, suggestingq Supplementary data associated with this article can be found, in the
online version, at doi:10.1016/j.febslet.2004.06.010.
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doi:10.1016/j.febslet.2004.06.010that ING1 could be a novel candidate tumor suppressor
[1,4–11].
Other members of the ING gene family, ING2/ING1L,
ING3, ING4 and ING5, were also isolated and characterized
[12–17]. Like ING1b, ING2 could negatively regulate cell
proliferation in a p53-dependent manner through induction of
G1 phase arrest of cell cycle and apoptosis [12]. ING3 could
activate p53-transactivated promoters, including promoters of
p21 and Bax, and induce a decreased population of cells in S
phase and apoptosis [13]. ING4, described as ING1 homolog
(GenBank Accession Nos. AF110645 or NM_016162), was
isolated from human pituitary by our previous works [16]. In
addition, Shiseki et al. [17] also described some characteristics
of ING4 and ING5, which the transient overexpression of
ING4 or ING5 could induce a decreased cell population in S
phase of cell cycle and apoptosis in a p53-dependent manner,
along with the increased p21 expression in RKO cells. More-
over, ING4 could physically interact with p300 and p53 in vivo,
as well as enhance p53 acetylation at Lys-382. Most interest-
ingly, Garkavtsev et al. [18] reported that ING4 was involved in
regulating brain tumor growth and angiogenesis by associating
with p65(RelA) subunit of NF-jB. In this study, we ﬁrst found
that ING4 could regulate negatively the cell growth with sig-
niﬁcant G2/M arrest of cell cycle and enhance chemosensitivity
to certain DNA-damage agents in HepG2 cells.2. Materials and methods
2.1. Plasmids constructs
The entire open reading frame of human ING4 was subcloned into
mammalian cell expression vectors pcDNA3.0 (Invitrogen) and
pcDNA3.1-cMyc-his (Invitrogen). pGEX5x-1-ING4 was constructed
to produce the GST-ING4 fusion protein for generating antibody
against human ING4.
2.2. Cell culture
HepG2 cells were cultured in MEM with 10% fetal bovine serum.
2 105 HepG2 cells were plated in 35-mm dishes and cultured at 37 C
for 24 h, and then were transfected with 5 lg of pcDNA 3.0-ING4,
pcDNA-3.1-ING4-cMyc-his or control plasmids, respectively, by using
ProFection Mammalian Transfection System (Promega). After 48 h,
we split the transfected cells into 100-mm dishes by 1:10 dilution and
subsequently screened by G418 for three weeks. The single cell clones
were picked, and then veriﬁed by reverse transcriptase-PCR and wes-
tern blot analysis. Saos-2 cells were cultured in McCoy’s 5a mediumblished by Elsevier B.V. All rights reserved.
Fig. 1. The constitutive overexpression of ING4 negatively regulated
the cell proliferation in HepG2 cells in vitro and in vivo. (A) Western
blot analysis demonstrated the overexpression of ING4 or cMyc-his
tagged ING4 in the stably transfected HepG2 cell clones, A3, P28, B3
and D5. (B) MTS assay (Promega) was employed to measure the cell
viability, which indicated that HepG2 cell clones with exogenous ING4
(A3, P28, B3) or cMyc-his tagged ING4 (D5) exhibited the decreased
cell proliferation compared with control clones with empty vectors
alone (V1, V2 and V3.1). Experiments were repeated at least thrice,
and the means and S.D. are included. (C) Decreased tumorigenicity of
HepG2 cells with constitutive expression of ING4 in nude mice. The
tumorigenicity of A3 and D5 cells was signiﬁcantly inhibited compared
with that of control clones. Experiments were performed two times,
four mice were used per group. (P < 0:05) The means and S.D. are
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3.0 and pcDNA3.0-ING4, respectively, by LipofectAMINE (Invitro-
gen). After 48 h, the cell lysates were collected for western blot
analysis.
2.3. Cell proliferation, cell cycle and ﬂow cytometry analysis
To observe the cell proliferation, the stable HepG2 subclones with
overexpression of ING4 were seeded in 96 well plate at 5 103 cells per
cm2 and cultured for 7 days. Cell viability was measured by MTS [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophe-
nyl)-2H-tetrazolium] dye reduction assay (Promega) during the time
course according to the manufacturer’s instructions. Simultaneously,
the direct cell counting was also performed at the same time points in
24-well plates. To analyze the cell cycle, the derived HepG2 cells were
harvested prior to conﬂuence, and ﬁxed with 70% (vol/vol) ethanol,
and then re-suspended in PBS buﬀer containing 20 lg/ml propidium
iodide and 500 lg/ml RNase A. The DNA contents were measured as
the propidium iodide signal to determine cell cycle proﬁles using
FACScan (Becton–Dickinson) and then analyzed by motFIT software.
At least 10 000 cells were analyzed from each sample. To evaluate the
chemosensitivity of HepG2 cells to some DNA-damage agents, the
cells were plated into 24-well plate at 1 104 cells per cm2, and sub-
sequently treated with doxorubicin (DOX) and etoposide (ETO), re-
spectively. The cell cycle proﬁles of the treated cells were analyzed after
48 h and the Sub-G1 population was considered as death cells. All
experiments were repeated at least thrice.
2.4. Tumorigenicity of HepG2 cells constitutively overexpressing ING4
Female athymic BLAB/cA nu mice, 5–6 weeks of age, were obtained
from SIPPR-BK Experimental Animal Co. (Shanghai, China) and
housed in a pathogen-free facility. 5 106 cells with overexpression
of ING4 were injected subcutaneously into the right ﬂank of nude
mice. Tumor growth was measured using caliper every 3 days and
the tumor volumes were calculated according to the formula:
volume¼ length (width2)/2. The tumorigenic experiments in vivo
were repeated twice with four mice each group.
2.5. Detection of apoptotic cells
HepG2 cells with stable overexpression of ING4 were plated on
coverslips and cultured overnight to allow the cells attaching to the
coverslips. The cells were further cultured for 4 and 5 days in serum
free medium and the apoptotic cells were detected with Annexin V-
FITC binding assay (BD Bioscience) [19]. Simultaneously, the DAPI
staining on the cells was also employed to quantitate the percent of
apoptotic cells.
2.6. Antibodies
Mouse monoclonal anti-p53 (DO-1), p21 (F-5), p27KIP1 (F-8) and
actin (C-2), cyclin B1(GSN1) and CDC2 were purchased from Santa
Cruz biotechnology (Santa Cruz). Rabbit polyclonal anti-ING4 anti-
body was raised against GST-ING4 fusion protein and puriﬁed from
antiserum with agarose-linked Protein G (Amersham). The anti-GST
antibody was removed by GST coupled with agarose beads.shown for each time point.3. Results and discussion
3.1. ING4 regulate negatively the cell growth of HepG2 cells
in vitro and in vivo
The previous studies from several groups implicated that
some members of the ING family could negatively regulate the
cell growth through diﬀerent model systems [9,12,13,17,20]. To
investigate the eﬀects of ING4 on cell proliferation, we es-
tablished some stable HepG2 cell lines with constitutive
overexpression of ING4. In this work, three subclones (A3,
P28 and B3) with exogenous ING4, and additional one (D5)
expressing Myc-tagged ING4, were screened out; meanwhile,
V1 and V2 subclones with the empty vector pcDNA3.0 alone,
as well as V3.1 with the empty vector pcDNA3.1-cMyc-his,
were served as the negative control, respectively (Fig. 1A).
These derived HepG2 subclones were seeded in 96-well plates,and then the cell viability was measured by MTS assay on the
cultured days, 1, 3, 5 and 7 days, respectively. Interestingly, the
cell proliferation of all HepG2 clones, A3, P28 and B3, with
constitutive overexpression of ING4 were signiﬁcantly re-
duced, the cell viability was decreased as much as 45–64% on
the 7th day compared with that of control clones (Fig. 1B left);
and, moreover, the cell growth of D5 clone with the cMyc-
tagged ING4 was more obviously inhibited than that of con-
trol clone (Fig. 1B right). The similar results were obtained by
direct cell counting in the same time course (data not shown).
These data suggested that the constitutive overexpression of
ING4 could negatively regulate the cell growth of HepG2 cells
in vitro.
To further strengthen the evidences, the tumorigenicity of
stable clones A3 and D5 with exogenous ING4 was observed
in nude mice by s.c. injection, as V3.1 and V1 subclones were
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clones was signiﬁcantly decreased as compared with control
groups (Fig. 1C), suggesting that the overexpression of ING4
indeed could suppress the cell growth of HepG2 cells in vivo.
3.2. The overexpression of ING4 induced the G2/M arrest of
cell cycle
To explore the intrinsic mechanism by which the overex-
pression of ING4 inhibits cell growth, cell cycle analysis was
performed on the stable HepG2 clones with or without exog-
enous ING4. Interestingly, the signiﬁcantly increased per-
centages of cells in G2/M phase, along with the dramatically
decreased cell population of G1 phase, were observed in P28,
B3, A3 and D5 clones overexpressing ING4 or cMyc-tagged
ING4, not in clones with empty vector alone (Fig. 2A and B).
Moreover, the extent of G2/M arrest seems to be correlated
with the dose of ING4 protein in the HepG2 clones, in which
A3 and D5 clones with the highest expression of ING4 ex-
hibited the most signiﬁcant G2/M arrest (Fig. 2C). These data
suggested that ING4 could inhibit the cell proliferation by
inducing the G2/M arrest in a dose-dependent manner in
HepG2 cells through regulating the G2 checkpoint. This ob-
servation is diﬀerent from the result obtained from transient
overexpression of ING4 in RKO cells, which showed a de-
creased cell population of S phase, along with the slightly in-
creased G1/G0 and G2/M phase [17]. The reason for why the
cellular behaviors induced by exogenous ING4 were diﬀerent
might be due to the distinct cell lines in both studies, or the
chronic eﬀect of ING4 on HepG2 cells.Fig. 2. Eﬀects of ING4 on cell cycle proﬁles of HepG2 cells. (A) The cell
overexpression. The percentages of cell population of diﬀerent cell cycle pha
tagged ING4 dramatically exhibited the G2/M cell cycle arrest with 83% cel
phases in the HepG2 cell clone. Experiments were repeated at least three time
showed the means and S.D., respectively.3.3. ING4 enhanced apoptosis on HepG2 cells
To evaluate the eﬀect of ING4 on apoptosis, some stable
HepG2 clones were cultured in serum-free medium for 4 and 5
days to trigger apoptosis by serum starvation. FITC-linked
annexin V/propidium iodide staining assay revealed that the
fraction of apoptotic cells in A3 and D5 clones was signiﬁ-
cantly greater than that in V1 and V3.1 as control (Fig. 3A and
supplementary Fig. S1). Similar results were obtained by
DAPI staining on the cells through counting the apoptotic cells
with small and condensed nucleus (data not shown). More-
over, quantitative examination in time course indicated that
the cell death was increased up to 20% in A3 and D5 clones
with the stable overexpression of ING4, as compared with that
of V1 and V3.1 clones as control at 4 days after serum star-
vation (Fig. 3B). The data suggested that ING4, as a condi-
tional inducer, could enhance apoptosis of HepG2 cells
triggered by serum starvation.
3.4. The G2/M arrest in HepG2 cells could be induced through
upregulation of p21 in a p53-dependent manner triggered by
ING4
The previous studies revealed that the functions of ING gene
family could be correlated with p53 [9,12,13,17]. ING4 has
been found to associate with p53 protein through the physical
interaction and enhancing p53 acetylation at Lys-382 residues
in RKO cells [17]. In this study, ING4 was proved to interact
physically with p53 in HepG2 cells using the co-immunopre-
cipitation assay (supplementary Fig. S2). p53 can regulate the
transcriptional expression of several downstream genes, suchcycle proﬁles in the HepG2 cell clones P28, B3 and A3 with ING4
ses were showed in upper-right. (B) The D5 cell clone with c-Myc-his
l population. (C) Distribution of cell population of diﬀerent cell cycle
s. *P < 0:01 compared with control clones. Data values and error bars
Fig. 3. Eﬀect of ING4 on apoptosis induced by serum starvation. (A) The derived HepG2 clones, V1, A3. V3.1 and D5, were cultured in serum free
medium for 4 and 5 days and stained with Annexin V-FITC/PI solution. The apoptotic cells were visualized under ﬂuorescence microscopy. Results
were indicated as the percentages of the number of apoptotic cells compared with total number of cells in ﬁve random samples. *P < 0:01 compared
with control clones. Data are means of three independent experiments. (B) HepG2 cells of V1, A3, V3.1 and D5 were evaluated in cell culture by
serum free medium for 0, 1, 2, 3 and 4 days as time course. Cell viability was measured using MTS assay. Experiments were repeated at least three
times, and the means and S.D. are included.
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apoptosis. Northern blotting and western blotting were em-
ployed to evaluate the transcriptional and translational levels
of these genes on the stably transfected HepG2 cells. The
Northern blot analysis on A3 cells showed that the transcripts
of p21 and Bax were signiﬁcantly increased although the
transcriptional level of p53 was not obviously regulated byFig. 4. The ING4-induced expression of some genes involved in cell cycle and
showed the eﬀect of ING4 on the transcriptional expressions of p53, p21, Bax
of exogenous ING4 protein after pcDNA3.0-ING4 transfection and G418 se
cell clones. The protein lysates were analyzed by western blotting with anti
Cruz). (C) p53-deﬁcient Saos-2 cells were transfected with pCDNA3.0-ING
blotting. (D) p21 associated with cyclin B1 in HepG2 cells. 400 lg cell lysate
linked protein A/G (Santa Cruz), and then the immunoprecipitate was ana
antibody, respectively. Precipitate from incubating the same cell lysates with a
lysate; Ct, negative control; IP, Immunoprecipitation.ING4 (Fig. 4A). However, GADD45, which has been reported
to play a critical role in G2/M arrest induced by ultraviolet
light or methyl methanesulfonate [21], was not increased.
Furthermore, Western blot analysis revealed that p21 protein
was signiﬁcantly elevated in the HepG2 subclones with exog-
enous ING4, not along with the increase of p53 protein
(Fig. 4B). Interestingly, the upregulation of p21 seems toapoptosis in the derived HepG2 cell clones. (A) Northern blot analysis
and GADD45. Mock: the stable HepG2 cell clone with no expression
lection. (B) The expression of p53, p21 and p27 proteins in the HepG2
-p53 antibody DO-1, anti-p21 antibody and anti-p27 antibody (Santa
4 and control vector. The expression of p21 was detected by western
from HepG2 cells was incubated with anti-p21 antibody and agarose-
lyzed by western blotting with anti-cyclin B1 antibody and anti-p21
garose-linked protein A/G alone was used as negative control. CL, cell
X. Zhang et al. / FEBS Letters 570 (2004) 7–12 11parallel with levels of ING4 protein and extent of G2/M arrest
in the stable HepG2 subclones. In contrast to p21, p27KIP1,
which is a member of Cip/Kip family belonging to cyclin ki-
nase inhibitors that are not regulated by p53, still maintained
the same level in the HepG2 clones with exogenous ING4 as
that in control cells (Fig. 4B). The data implied that ING4
could modulate the p53-inducible genes such as p21 and BAX,
but not GADD45, in a p53-dependent manner. To strengthen
the hypothesis, p53-deﬁcient Saos-2 cells were employed to
determine whether the p21 could be regulated by exogenous
ING4 in p53-independent manner. The result showed that the
overexpression of ING4 alone could not lead the upregulation
of p21 in the p53-deﬁcient Saos-2 cells (Fig. 4C), suggesting
that p53-dependent pathway triggered by ING4 could play an
important role in the upregulation of p21. However, except for
p53 pathway, p21 could also be regulated through p53-inde-
pendent pathways. Recently, ING4 was reported to interact
with p300 and p65 (RelA) subunit of NF-jB [17,18], suggest-
ing that ING4 could be involved in the p53-independent sig-
naling pathways, and ING4-induced upregulation of p21 and
Bax still needs to be further studied.
To explore the molecular mechanisms of G2/M arrest, we
analysed the levels of cyclin B1 and CDC2 in the stable HepG2
cell clones with exogenous ING4, since the cyclin B1/CDC2Fig. 5. ING4 could enhance the chemosensitivity to DNA-damage agents i
30 lg/ml ETO for 4 h. The expression of p53 and ING4 was detected by weste
A3, was performed after treated with DOX and ETO for 48 h. The cell popula
(C) HepG2 cells (A3 and P28) with ING4 overexpression could be facilitated
of three independent experiments from ﬂow cytometry analysis. (D) Similar e
sensitive to ETO, particularly in A3 clone. (*P < 0:05, **P < 0:01) The meacomplex is a known important regulator of G2/M transition.
However, the overexpression of ING4 did not regulate the
expression of cyclin B1 and CDC2 in HepG2 cells (supple-
mentary Fig. S3). Therefore, the regulation of cyclin B1 and
CDC2 expression could not be a major contributor to the
ING4-induced G2/M arrest in HepG2 cells. Previous studies
showed that p21 can inhibit CDC2 activity of cyclin B1/CDC2
complex and induced G2 arrest in various cells through
binding to cyclin B1/CDC2 complex [22–24]. Herein, co-im-
munoprecipitation experiment revealed that cyclin B1 could
physically associate with p21 in HepG2 cells (Fig. 4D), im-
plicating that the ING4-induced upregulation of p21 could
strengthen the association of cyclin B1 and p21, which may
contribute to the G2/M arrest in the HepG2 cells.
3.5. ING4 could enhance the chemosensitivity to DNA-damage
agents
Both ING1 and ING2 have been reported to enhance the
chemosensitivity to DNA-damage agents in various human
cells [12,13,25,26]. To evaluate the potential eﬀects of ING4 on
DNA damage, ETO and DOX were used to treat the HepG2
cells. ETO and DOX could induce the increasing expression of
p53, but not result in the signiﬁcant change of ING4 expres-
sion in HepG2 cells (Fig. 5A). However, the cell cycle analysisn HepG2 cells. (A) HepG2 cells were treated with 2 lg/ml DOX and
rn blotting. (B) Flow cytometry analysis on the HepG2 clones, V1 and
tion of subdiploid peak before G1 phase was considered as death cells.
into death as exposure to DOX for 48 h. The data were representatives
xperiments indicated that the recombinant HepG2 cells could be more
ns and S.D. are included.
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peak in A3 cells with ING4 overexpression, as the HepG2 cells
were treated with ETO or DOX, (Fig. 5B). As exposure to 0.02
lg/ml DOX, there were 13% death cells in A3 clone while only
4% in control clone V1. When DOX was increased to 0.2 lg/
ml, about 20% A3 cells were dead but only 7% in V1 cells,
indicating that the chemosensitivity to DOX in A3 cells was
elevated up to about 3-folds (Fig. 5C). More interestingly, as
exposure to 0.3 and 3 lg/ml of ETO, about 24% and 32% A3
cells could be dead while only 6% and 7% in V1 cells, respec-
tively, implying that ING4 could enhance the chemosensitivity
to ETO, up to 4–4.6-folds, which was more signiﬁcant than
that to DOX (Fig. 5D). Similarly, the somewhat increased cell
death also was occurred in P28 clone with slight ING4 over-
expression as exposure to the same DNA-damage agents, al-
though weaker than that of A3 cells (P < 0:05, Fig. 5C and D).
These results revealed that ING4 could enhance the cell death
triggered by DNA-damage agents in HepG2 cells, although
the expression of ING4 has no obvious response to DNA-
damage.
Taken together, this study suggested that the ING4 gene, as a
novel member of ING family, could negatively regulate cell
proliferation by inducing G2/M arrest that might be correlated
with upregulation of p21 induced by ING4; and, moreover,
enhanced apoptosis inducedby serum starvation inHepG2 cells.
Interestingly, ING4 could also enhance the chemosensitivity to
DNA-damage agents, implying that ING4 could be a candidate
for gene therapy, in combination with chemotherapeutics.
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